Advertisement

Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 6869 | Ordered by Date (descending)
1 2 3 ... 67 68 69  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Enterome–SEVERAL: investment, 202006 financing round Series E €na with existing plus new investors SymBiosis LLC + Takeda Pharma 2020-06-25
Enterome–SymBiosis LLC: investment, 202006 financing round Series E €na incl new investor SymBiosis LLC 2020-06-25
Enterome–Takeda: investment, 202006 financing round Series E €na incl new investor Takeda Pharmaceutical Co Ltd 2020-06-25
RareCyte–Scienion: single-cell dispenser, 202006 supply existent of cellenONE to RareCyte for CTC analysis technology by Cellenion 2020-06-22
Royalty Pharma–SEVERAL: investment, 202006 IPO $2.175b+$326m with 60m+17.7m+11.65m Class A ordinary shares at $28/share at Nasdaq Global Select Market 2020-06-18
DiogenX–Juvenile Diabetes Research Foundation: investment, 202006 seed financing round totalling €4.5m incl investor JDRF T1D Fund 2020-06-16
DiogenX–SEVERAL: investment, 202006 seed financing round €4.5m from Advent France Biotechnology + BIVF + JDRF T1D Fund 2020-06-16
eTheRNA–Novalis LifeSciences: investment, 202006 financing round Series B totalling €34m incl new investor Novalis LifeSciences LLC 2020-06-16
eTheRNA–Omega Funds: investment, 202006 financing round Series B totalling €34m incl existing investor Omega Funds 2020-06-16
eTheRNA–SEVERAL: investment, 202006 financing round Series B €34m from all existing + new investors 2020-06-16
GSK–Ideaya Biosciences: synthetic lethality, 202006– collab strategic partnership ww $100m upfront + milestones + royalties 2020-06-16
Ideaya Biosciences–GSK: investment, 202006 direct private placement $20m common stock purchase by GSK 2020-06-16
Bit Bio–ARCH Venture: investment, 202006 financing round Series A totalling $41.5m incl co-investor Arch Venture Partners 2020-06-13
Bit Bio–Foresite Capital: investment, 202006 financing round Series A totalling $41.5m incl co-investor Foresite Capital 2020-06-13
Bit Bio–Mission Group: public relations, 202006 service existent by April Six 2020-06-13
Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Bob Nelsen 2020-06-13
Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Jim Tananbaum 2020-06-13
Bit Bio–PERSON: investment, 202006 financing round Series A totalling $41.5m incl co-leadinvestor Rick Klaunser 2020-06-13
Bit Bio–SEVERAL: investment, 202006 financing round Series A $41.5m led by Rick Klaunser + Bob Nelsen + Jim Tananbaum 2020-06-13
JnJ–Bavarian Nordic: vaccine, 202006– supply $13.9m manufacturing + delivery of MVA-BN Filo Ebola vaccine to Janssen Vaccines & Prevention BV 2020-06-12
Lexent Bio–Roche: investment, 202006 acquisition of Lexent Bio by Foundation Medicine 2020-06-12
Corvidia Therapeutics–Goodwin Procter: legal services, 202006 supply service legal advisor to Cordivia for acquisition by Novo Nordisk 2020-06-11
Corvidia Therapeutics–JPMorgan Chase: financial services, 202006 supply service advisor to Cordivia for acquisition by Novo Nordisk 2020-06-11
Corvidia Therapeutics–McDougall Communications: public relations, 202006 service existent by McDougall 2020-06-11
Corvidia Therapeutics–Novo Group: investment, 202006 acquisition $725m upfront cash + $1.375b milestones cash by Novo Nordisk ANNOUNCED 2020-06-11
Novo Group–Davis Polk & Wardell: legal services, 202006 supply service legal advisor to Novo Nordisk for acquisition of Corvidia Therapeutics 2020-06-11
10x Genomics–Merck (DE): CRISPR technology, 202006 collab launch integrated solution for CRISPR research 2020-06-10
Bioqube Ventures–JnJ: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investorj JnJ Innovation 2020-06-10
Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al 2020-06-10
Protera–SEVERAL: investment, 202006 financing round Series A $5.6m led by Sofinnova Partners + incl existing investor SOSV 2020-06-10
Royalty Pharma–AiCuris: letermovir, 202006 acquisition of partial royalty interest on letermovir for one-time payment of $220m by Royalty Pharma 2020-06-09
Atlas Venture–SEVERAL: investment, 202006 closing of $400m Fund XII 2020-06-05
Tropic Biosciences–SEVERAL: investment, 202006 financing round Series B $28.5m led by Temasek 2020-06-04
Tropic Biosciences–Temasek: investment, 202006 financing round Series B totalling $28.5m incl new + lead investor Temasek 2020-06-04
NodThera–SEVERAL: investment, 202006 financing round Series B £44m ($55m) led by Novo Ventures 2020-06-03
Prilenia–Genworks 2: investment, 202006 financing round Series A totalling $62.5m incl existing + co-investor Genworks 2 2020-06-03
Prilenia–Sectoral Asset Management: investment, 202006 financing round Series A totalling $62.5m incl new + co-investor Sectoral Asset Management 2020-06-03
Prilenia–SEVERAL: investment, 202006 financing round Series A $62.5m led by new investor Forbion 2020-06-03
Prilenia–Talisman Capital Partners: investment, 202006 financing round Series A totalling $62.5m incl existing + co-investor Talisman Capital Partners 2020-06-03
Twist Bioscience–SEVERAL: investment, 202006 public offering $100m+$15m with 3m+455k shares common stock at $33/share 2020-06-03
Genmab–Rentschler: biologics contract manufacturing, 202005– collab expansion production of DuoBody products to new Rentschler US facility 2020-05-27
Argenx–SEVERAL: investment, 202005 global offering $862.5 via ADS offering in US + private placement in Europe 2020-05-26
Exscientia–SEVERAL: investment, 202005 financing round Series C $60m led by Novo Holdings + incl Evotec + BMS + GT Healthcare Capital 2020-05-26
Themis Bioscience–Merck (US): investment, 202005– acquisition €na all remaing shares of Themis via Merck subsidiary 2020-05-26
Poxel–Trophic Communications: public relations, 202005 service existent IR+ media EU/US by Trophic Communications 2020-05-25
Stratos–Roche: investment, 202005 acquisition €na of Stratos Genomics by Roche 2020-05-22
GSK–Samsung: biologicals contract manufacturing, 202005–2028 supply up to $231m of Benlysta + other biologics by Samsung Biologics 2020-05-21
HotSpot Therapeutics–Atlas Venture: investment, 202005 financing round Series B totalling $65m incl existing + co-investor Atlas Venture 2020-05-21
HotSpot Therapeutics–EMS (BR): investment, 202005 financing round Series B totalling $65m incl co-investor Cleva Pharma 2020-05-21
HotSpot Therapeutics–GSK: investment, 202005 financing round Series B totalling $65m incl lead investor SR One 2020-05-21
HotSpot Therapeutics–Merck (US): investment, 202005 financing round Series B totalling $65m incl co-investor MRL Ventures Fund 2020-05-21
HotSpot Therapeutics–SEVERAL: investment, 202005 financing round Series B $65m led by SR One 2020-05-21
HotSpot Therapeutics–Sofinnova: investment, 202005 financing round Series B totalling $65m incl existing + co-investor Sofinnova Partners 2020-05-21
HotSpot Therapeutics–Solasta Ventures: investment, 202005 financing round Series B totalling $65m incl co-investor Solasta Ventures 2020-05-21
HotSpot Therapeutics–Tekla Capital: investment, 202005 financing round Series B totalling $65m incl co-investor Tekla Capital Management 2020-05-21
HotSpot Therapeutics–Verge Scientific Communications: public relations, 202005 service existent by Verge 2020-05-21
Moderna–Morgan Stanley: financial services, 202005 supply service Morgan Stanley is sole book-running manager for up $1.54b public offering 2020-05-21
Nautilus Biotechnology–Walker Communications: public relations, 202005 service existent by Walker Communications 2020-05-21
Octant–8VC: investment, 202005 financing round Series A totalling $30m incl co-investor 8VC 2020-05-20
Octant–Allen & Co: investment, 202005 financing round Series A totalling $30m incl co-investor Allen & Co 2020-05-20
Octant–Andreessen Horowitz: investment, 202005 financing round Series A totalling $30m incl lead investor Andreessen Horowitz 2020-05-20
Octant–SEVERAL: investment, 202005 financing round Series A $30m led by Andreessen Horowitz 2020-05-20
Octant–SV Angel: investment, 202005 financing round Series A totalling $30m incl co-investor SV Angel 2020-05-20
Idorsia–SEVERAL: investment, 202005 capital increase CHF330m offering of 11m new shares at CHF30/share to qualified investors 2020-05-19
Phlow–United States (govt): grant, 202005– BARDA contract $354m for 4y plus optional $458m to secure domestic drug production in US 2020-05-19
Holmusk–Health Catalyst Capital: investment, 202005 financing round Series A totalling $21.5m incl co-lead investor Health Catalyst Capital 2020-05-18
Holmusk–Heritas Capital: investment, 202005 financing round Series A totalling $21.5m incl existing + co-investor Heritas Capital 2020-05-18
Holmusk–SEVERAL: investment, 202005 financing round Series A $21.5m co-led by Optum Ventures + Health Catalayst Capital 2020-05-18
Holmusk–UnitedHealth: investment, 202005 financing round Series A totalling $21.5m incl co-lead investor Optum Ventures 2020-05-18
Moderna–SEVERAL: investment, 202005 public offering $1.34b+$200.6m with 17.6m+2.64m shares common stock at $76/share 2020-05-18
Nautilus Biotechnology–Allen Group: investment, 202005 financing round Series B totalling $76m incl new + lead investor Vulcan Capital 2020-05-18
Nautilus Biotechnology–AME Cloud Ventures: investment, 202005 financing round Series B totalling $76m incl existing + co-investor AME Cloud Ventures 2020-05-18
Nautilus Biotechnology–Andreessen Horowitz: investment, 202005 financing round Series B totalling $76m incl existing + co-investor Andreessen Horowitz 2020-05-18
Nautilus Biotechnology–Bezos Group: investment, 202005 financing round Series B totalling $76m incl new + co-investor Bezos Expeditions 2020-05-18
Nautilus Biotechnology–Bolt: investment, 202005 financing round Series B totalling $76m incl existing + co-investor Bolt 2020-05-18
Nautilus Biotechnology–Defy Partners: investment, 202005 financing round Series B totalling $76m incl new + co-investor Defy Partners 2020-05-18
Nautilus Biotechnology–Madrona Venture: investment, 202005 financing round Series B totalling $76m incl existing + co-investor Madrona Venture Group 2020-05-18
Nautilus Biotechnology–Perceptive Advisors: investment, 202005 financing round Series B totalling $76m incl new + co-investor Perceptive Advisors 2020-05-18
Nautilus Biotechnology–SEVERAL: investment, 202005 financing round Series B $76m led by Vulcan Capital 2020-05-18
Calliditas Therapeutics–SEVERAL: investment, 202005– filing of US IPO of ADSs at Nasdaq Global Market 2020-05-14
Calliditas Therapeutics–SEVERAL: investment, 202005– private placement outside US announced concurrent filing of US IPO of ADSs 2020-05-14
Immunai–SEVERAL: investment, 202005 seed financing round $20m co-led by Viola Ventures + TLV Partners announced at emergence from stealth 2020-05-14
Immunai–TLV Partners: investment, 202005 seed financing round totalling $20m incl co-lead investor TLV Partners 2020-05-14
Immunai–Viola Ventures: investment, 202005 seed financing round totalling $20m incl co-lead investor Viola Ventures 2020-05-14
Optibrium–OpenEye Scientific: cheminformatics, 202005– collab product integration OE libraries + toolkits with StarDrop software 2020-05-12
Bluebird Bio–Hitachi: contract manufacturing, 202005– supply expansion long-term developm + manufacturing by HCATS + Apceth for gene therapies 2020-05-11
Novartis–Dyno Therapeutics: gene therapy, 202005– collab design of AVV vectors for ophthalmic gene therapies using AI-based CapsidMap platform 2020-05-11
Oncopeptides–SEVERAL: investment, 202005 directed share issue SEK1.414b ($144m) with 12.295m new shares at SEK115/share 2020-05-05
Stemline Therapeutics–Menarini: investment, 202005– acquisition up to $677m ANNOUNCED 2020-05-04
ADC Therapeutics–Deerfield: credit, 202005– convertible credit facility $115m in two conditionable disbursements of $65m + $50m 2020-05-01
Moderna–Lonza: biologicals contract manufacturing, 202005–203004 collab strategic 10y manufacture of mRNA1273 vaccine + other Moderna products 2020-05-01
Lyra Therapeutics–SEVERAL: investment, 202004–202005 IPO $56m+$8.4m with 3.5m+525k shares commonc stock at $16/share at Nasdaq Global Market 2020-04-30
Pfizer–Valneva: Lyme disese vaccine, 202004– collab developm of VLA15 + commerc by Pfizer $130m upfront + $178m milestones + 2-digit tiered royalties 2020-04-30
Polyplus-transfection–Warburg Pincus: investment, 202004 investment resulting in Warburg Pincus + ArchiMed owning equal shares + voting rights 2020-04-29
Robocath–SEVERAL: investment, 202004 financing round Series C €40m led by MicroPort Scientific 2020-04-29
Taysha Gene Therapies–SEVERAL: investment, 202004 seed financing round $30m co-led by PBM Capital + Nolan Capital 2020-04-29
Compass Pathways–ATAI Life Sciences: investment, 202004 financing round Series B totalling $80m incl existing investor ATAI Life Sciences 2020-04-27
Compass Pathways–Otsuka: investment, 202004 financing round Series B totalling $80m incl new investor MSRD 2020-04-27
Compass Pathways–Perceptive Advisors: investment, 202004 financing round Series B totalling $80m incl new investor Perceptive Advisors 2020-04-27
Compass Pathways–SEVERAL: investment, 202004 financing round Series B $80m from existing + new investors 2020-04-27
1 2 3 ... 67 68 69  next pagenext page



Advertisement

Picture [iito] Männer Ballett 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80

» top